Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SPP007
MIFTS: 39

Suppression Amblyopia

Categories: Neuronal diseases
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Suppression Amblyopia

About this section

MalaCards integrated aliases for Suppression Amblyopia:

Name: Suppression Amblyopia 12 15
Amblyopia 43 71
Amblyopia, Suppression 71
Strabismic Amblyopia 12

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:10375
ICD9CM 34 368.01
MeSH 43 D000550
SNOMED-CT 67 35600002
ICD10 32 H53.03
UMLS 71 C0002418 C0750903
Sources

Summaries for Suppression Amblyopia

About this section
MalaCards based summary : Suppression Amblyopia, also known as amblyopia, is related to paralytic squint and astigmatism, and has symptoms including photophobia, other specified visual disturbances and visual disturbance. An important gene associated with Suppression Amblyopia is PLAAT3 (Phospholipase A And Acyltransferase 3). The drugs Tropicamide and Atropine have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and cortex.

Sources

Related Diseases for Suppression Amblyopia

About this section

Diseases related to Suppression Amblyopia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 265)
# Related Disease Score Top Affiliating Genes
1 paralytic squint 32.0 PHOX2A MTRNR2L5
2 astigmatism 31.9 NBL1 DSE
3 esotropia 31.0 PLAAT3 PHOX2A DSE
4 exotropia 30.6 TNFRSF10C PLAAT3 PHOX2A
5 accommodative esotropia 30.6 PLAAT3 PHOX2A
6 aniseikonia 30.5 PLAAT3 DSE
7 hypotropia 30.4 PLAAT3 PHOX2A
8 hypertropia 30.4 PLAAT3 PHOX2A
9 monofixation syndrome 30.3 TNFRSF10C PLAAT3
10 ocular motility disease 30.2 PLAAT3 PHOX2A
11 cycloplegia 30.1 NBL1 DSE
12 anisometropia 30.0 TNFRSF10C PLAAT3 NBL1 DSE A1CF
13 strabismus 29.6 TNFRSF10C PLAAT3 PHOX2A DSE
14 amblyopia 29.3 TNFRSF10C SIRPA PLAAT3 PHOX2A HNMT DSE
15 facial paralysis 29.2 MTRNR2L5 MTRNR2L4
16 ametropic amblyopia 28.7 PHOX2A NBL1 MTRNR2L5 MTRNR2L4 DSE
17 disuse amblyopia 12.5
18 mental and growth retardation with amblyopia 12.2
19 microphthalmia, isolated 6 11.6
20 farsightedness 11.6
21 duane retraction syndrome 1 11.6
22 microphthalmia 11.4
23 peters-plus syndrome 11.4
24 hemifacial hyperplasia with strabismus 11.4
25 isolated ectopia lentis 11.4
26 blepharophimosis, ptosis, and epicanthus inversus 11.2
27 duane retraction syndrome 2 11.2
28 corneal dystrophy, congenital stromal 11.2
29 bestrophinopathy, autosomal recessive 11.2
30 cerulean cataract 11.2
31 aniridia 1 11.1
32 aniridia and absent patella 11.1
33 cataract 41 11.1
34 fibrosis of extraocular muscles, congenital, 1 11.1
35 bornholm eye disease 11.1
36 fibrosis of extraocular muscles, congenital, 3a, with or without extraocular involvement 11.1
37 mental retardation, anterior maxillary protrusion, and strabismus 11.1
38 cognitive impairment with or without cerebellar ataxia 11.1
39 duane retraction syndrome 3 with or without deafness 11.1
40 aniridia 2 11.1
41 catifa syndrome 11.1
42 cataract microcornea syndrome 11.1
43 hivep2-related intellectual disability 11.1
44 isolated duane retraction syndrome 11.1
45 monocular esotropia 10.8
46 ptosis 10.6
47 refractive error 10.6
48 eye disease 10.6
49 pathologic nystagmus 10.6
50 ocular dominance 10.5

Graphical network of the top 20 diseases related to Suppression Amblyopia:



Diseases related to Suppression Amblyopia
Sources

Symptoms & Phenotypes for Suppression Amblyopia

About this section

UMLS symptoms related to Suppression Amblyopia:


photophobia, other specified visual disturbances, visual disturbance
Sources

Drugs & Therapeutics for Suppression Amblyopia

About this section

Drugs for Suppression Amblyopia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tropicamide Approved, Investigational Phase 4 1508-75-4 5593
2
Atropine Approved, Vet_approved Phase 4 51-55-8, 5908-99-6 174174
3
Donepezil Approved Phase 4 120014-06-4 3152
4
Brinzolamide Approved Phase 4 138890-62-7 68844
5
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
6
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
7
Cefpirome Approved Phase 4 84957-29-9 5479539
8
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
9
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
10 Mydriatics Phase 4
11 Respiratory System Agents Phase 4
12 Parasympatholytics Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Muscarinic Antagonists Phase 4
15 Cholinergic Antagonists Phase 4
16 Bronchodilator Agents Phase 4
17 Cholinesterase Inhibitors Phase 4
18 Ophthalmic Solutions Phase 4
19 Anti-Inflammatory Agents Phase 4
20 Carbonic Anhydrase Inhibitors Phase 4
21 Ketorolac Tromethamine Phase 4
22 Analgesics, Non-Narcotic Phase 4
23 Analgesics Phase 4
24 Cyclooxygenase Inhibitors Phase 4
25 Antirheumatic Agents Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Anti-Infective Agents Phase 4
28 Anti-Bacterial Agents Phase 4
29 Norgestimate, ethinyl estradiol drug combination Phase 4
30 Antibiotics, Antitubercular Phase 4
31 Sodium Channel Blockers Phase 4
32 Sympatholytics Phase 4
33 Diuretics, Potassium Sparing Phase 4
34
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
35
Levodopa Approved Phase 3 59-92-7 6047
36
Carbidopa Approved Phase 3 28860-95-9 34359
37
Acetazolamide Approved, Vet_approved Phase 2, Phase 3 59-66-5 1986
38
Acetaminophen Approved Phase 2, Phase 3 103-90-2 1983
39
Ibuprofen Approved Phase 2, Phase 3 15687-27-1 3672
40
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
41
Guaifenesin Approved, Investigational, Vet_approved Phase 2, Phase 3 93-14-1 3516
42
Codeine Approved, Illicit Phase 2, Phase 3 76-57-3 5284371
43
Aspirin Approved, Vet_approved Phase 2, Phase 3 50-78-2 2244
44 Dopamine Agents Phase 3
45 Antiparkinson Agents Phase 3
46 Aromatic Amino Acid Decarboxylase Inhibitors Phase 3
47 Antitussive Agents Phase 2, Phase 3
48 Narcotics Phase 2, Phase 3
49 Fibrinolytic Agents Phase 2, Phase 3
50 Platelet Aggregation Inhibitors Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 171)
# Name Status NCT ID Phase Drugs
1 Pilot Study of Prevention Myopia in Children With Low Concentration of Atropine Unknown status NCT00541177 Phase 4 atropine;tropicamide
2 The Effect of Donepezil on Perceptual Learning in Adult Amblyopia Completed NCT03109314 Phase 4 Donepezil
3 A Randomized Trial Comparing Daily Atropine Versus Weekend Atropine Completed NCT00094614 Phase 4 Atropine
4 Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome Completed NCT01312402 Phase 4 topical brinzolamide 1% in 5mL ophthalmic medication;Placebo in 5 mL dispenser
5 Mini-flared Kelman Tip and Reverse Tip With Torsional Phaco: Prospective Randomized Comparative Study Completed NCT02089698 Phase 4
6 Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study Completed NCT02084576 Phase 4 Nepafenac;Ketorolac
7 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
8 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
9 Topical Timolol for the Treatment of Benign Vascular Periocular Lesions Withdrawn NCT01250457 Phase 4 topical Timolol
10 Clinical Evaluation of the Use of Sealed Capsule Irrigation With Sodium Chloride During Pediatric Cataract Surgery and IOL Implantation Withdrawn NCT00366613 Phase 4
11 Vision In Preschoolers Study (VIP Study) Unknown status NCT00038753 Phase 3
12 Anisometropia Amblyopia Improved by Perceptual Learning and Patching Completed NCT00498641 Phase 3
13 A Randomized Trial of Levodopa as Treatment for Residual Amblyopia (ATS 17) Completed NCT01190813 Phase 3 Levodopa/Carbidopa;Placebo
14 A Randomized Trial Comparing Part-time Versus Minimal-time Patching for Moderate Amblyopia Completed NCT00094679 Phase 3
15 Increasing Patching for Amblyopia in Children 3 to < 8 Years Old Completed NCT00945100 Phase 3
16 A Randomized Trial Comparing Near Versus Distance Activities While Patching for Amblyopia in Children 3 to <7 Years Old Completed NCT00315198 Phase 3
17 A Randomized Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye As Prescribed Treatments for Amblyopia in Children 3 to <7 Years Old Completed NCT00315302 Phase 3 Atropine
18 A Randomized Trial Comparing Part-time Versus Full-time Patching for Severe Amblyopia Completed NCT00094744 Phase 3
19 Electronic Recording of Compliance With Occlusion Therapy for Amblyopia: 1 Effects of Patient Education on Compliance 2 Predictors for Non-Compliance Completed NCT00131729 Phase 3
20 Amblyopia Treatment Study: Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia Completed NCT00000170 Phase 3 Atropine
21 Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old Completed NCT00944710 Phase 3 Atropine;Atropine
22 An Evaluation of Treatment of Amblyopia in 7 To <18 Year Olds Completed NCT00094692 Phase 3 atropine
23 Amblyopia Treatment Study Completed NCT00001864 Phase 3 Atropine
24 A Randomized Trial of Full-time Bangerter Filters Versus Part-time Daily Patching for the Treatment of Moderate Amblyopia in Children Completed NCT00525174 Phase 3
25 A Randomized Trial to Evaluate 2 Hours of Daily Patching for Amblyopia in Children 3 to <7 Years Old Completed NCT00091923 Phase 3
26 A Randomized Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds Completed NCT00315328 Phase 3 Atropine
27 Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity Completed NCT01203436 Phase 2, Phase 3
28 A Multicenter, Double-blind, Randomized, Placebo-controlled Study of Weight-Reduction and/or Low Sodium Diet Plus Acetazolamide vs Diet Plus Placebo in Subjects With Idiopathic Intracranial Hypertension With Mild Visual Loss Completed NCT01003639 Phase 2, Phase 3 Acetazolamide;Placebo
29 A Randomized Trial Comparing Patching With Active Vision Therapy to Patching With Control Vision Therapy as Treatment for Amblyopia in Children 7 to <13 Years Old Terminated NCT00587171 Phase 3
30 A Randomized Trial to Evaluate Combined Patching-Atropine for Residual Amblyopia Terminated NCT00506675 Phase 3 Atropine;Atropine
31 A Novel Therapeutic Strategy Targeting Photoreceptor Oxidative Damage in ABCR-related Retinal Degenerations Unknown status NCT01278277 Phase 1, Phase 2
32 Is Non-cycloplegic Photorefraction Applicable for Screening Refractive Risk Factors of Amblyopia? Completed NCT01308307 Phase 2
33 A Pilot Study to Evaluate Levodopa as Treatment for Residual Amblyopia in 8 to 17 Year Olds Completed NCT00789672 Phase 2 levodopa/carbidopa;levodopa/carbidopa
34 Effectiveness of Telescopic Magnification in the Treatment of Amblyopia Completed NCT00970554 Phase 1, Phase 2
35 Evaluation and Development of a Novel Binocular Treatment (I-BiTTM) System Using Video Clips and Interactive Games to Improve Vision in Children With Amblyopia ('Lazy Eye'). Completed NCT01702727 Phase 2
36 Comparison of Photorefraction With Cycloautorefraction and Cycloretinoscopy at Emam Hosein Medical Centre in 2008-2009 Completed NCT00815581 Phase 1, Phase 2
37 Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants Completed NCT00349726 Phase 2 Inositol lower volume;Inositol higher volume;Placebo lower volume;Placebo higher volume
38 Phase II Randomized, Double-Masked, Placebo-Controlled, Safety, Pharmacokinetic, and Dose-Ranging Study of Multiple Doses of Inositol in Premature Infants Completed NCT01030575 Phase 2 Inositol lower volume;Inositol mid-level volume;Inositol high volume;Placebo low volume
39 THOR - Tübingen Choroideremia Gene Therapy Trial Open Label Phase 2 Clinical Trial Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1) Active, not recruiting NCT02671539 Phase 2
40 Pilot Study to Evaluate Docosahexaenoic Acid as Treatment for Residual Amblyopia Not yet recruiting NCT03402789 Phase 1, Phase 2 Docosahexaenoic Acid;Placebo Oral Tablet
41 Caffeine in Amblyopia Study Withdrawn NCT02594358 Phase 1, Phase 2 Caffeine
42 Randomised Occlusion Treatment of Amblyopia Study (ROTAS): Trial of Maximal Vs Substantial Doses of Occlusion to Evaluate Visual Outcome for Children With Amblyopia Completed NCT00274664 Phase 1
43 Investigation of Visual Plasticity by a Direct Current Stimulation of Occipital Cortex in Adult Amblyopia Completed NCT00097162 Phase 1
44 A Singapore Pilot Study To Evaluate The Efficacy Of A Computerized System For The Vision Improvement Of People With Low Myopia Completed NCT00348127 Phase 1
45 Monovision for Treatment of Diplopia Completed NCT01426672 Phase 1
46 A Randomized, Three-Sequence, Three-Period Crossover Study to Assess the Bioavailability and Pharmacokinetics of a Single Dose of Atropine Administered Sublingually in Healthy Adult Volunteers Completed NCT04290039 Phase 1 Atropine Sulfate Ophthalmic Solution;Atropine Sulphate Injection
47 Pilot Study To Evaluate The Efficacy Of Neurovision'S NVCâ„¢- Vision Correction Technology For The Improvement In Visual Acuity In Myopic Children And Slowing Down Of Myopia Progression Completed NCT00348218 Phase 1
48 Recovery From Amblyopia With Cholinesterase Inhibitors Recruiting NCT01584076 Phase 1 Donepezil
49 Dichoptic Virtual Reality Therapy for Amblyopia in Adults Terminated NCT02246556 Phase 1
50 Phase 1 Study of Topical Beta Blocker to Prevent the Proliferative Stage of Infantile Hemangioma Terminated NCT01434849 Phase 1 topical 0.5% Timolol maleate;Control (placebo) group

Search NIH Clinical Center for Suppression Amblyopia

Cochrane evidence based reviews: amblyopia

Sources

Genetic Tests for Suppression Amblyopia

About this section
Sources

Anatomical Context for Suppression Amblyopia

About this section

MalaCards organs/tissues related to Suppression Amblyopia:

40
Eye, Testes, Cortex, Brain, Retina, Endothelial, Pituitary
Sources

Publications for Suppression Amblyopia

About this section

Articles related to Suppression Amblyopia:

(show top 50) (show all 7132)
# Title Authors PMID Year
1
Short-term monocular deprivation reduces inter-ocular suppression of the deprived eye. 61
32460171 2020
2
Quantitative analysis of macular and peripapillary microvasculature in adults with anisometropic amblyopia. 61
32200510 2020
3
Abnormal Red Reflex: Etiologies in a Pediatric Ophthalmology Population. 61
32503396 2020
4
Consecutive strabismus after infantile nystagmus syndrome surgery and potential risk factors. 61
32307586 2020
5
Evaluating Amblyopia Treatment Success Using the American Academy of Ophthalmology IRIS50 Measures. 61
32199623 2020
6
Femtosecond Laser-Assisted LASIK in Children With Hyperopia and Anisometropic Amblyopia: 7 Years of Follow-up. 61
32521023 2020
7
Transcranial Magnetic Stimulation in Adults With Amblyopia. 61
31453915 2020
8
Analysis of the potential impact of strabismus with and without amblyopia on visual-perceptual and visual-motor skills evaluated using TVPS-3 and VMI-6 tests. 61
32535162 2020
9
Benefit of Patching Therapy to Minimize Amblyopia After Retinoblastoma Treatment. 61
32507274 2020
10
Associations between Attention-Deficit/Hyperactivity Disorder and Ocular Abnormalities in Children: A Population-based Study. 61
31878821 2020
11
Contributing ocular comorbidity to end-of-life visual acuity in medically treated glaucoma patients, ocular hypertension and glaucoma suspect patients. 61
32494040 2020
12
VEP estimation of visual acuity: a systematic review. 61
32488810 2020
13
Efficacy of toric intraocular lens implantation with high corneal astigmatism within the United Kingdom's National Health Service. 61
31844167 2020
14
Clinical safety and efficacy of a hydrophilic acrylic intraocular lens in a real-world population: a 1-year follow-up retro-prospective study. 61
32527240 2020
15
Presentation, surgery and 1-year outcomes of childhood cataract surgery in Tanzania. 61
32522793 2020
16
The rare phenomenon of Marcus-Gunn jaw winking without ptosis: Report of 14 cases and review of the literature. 61
32461447 2020
17
Understanding the Impact of Residual Amblyopia on Functional Vision and Eye-Related Quality of Life using the PedEyeQ. 61
32511967 2020
18
Predictive factors for the perceptual learning in stereodeficient subjects. 61
32561200 2020
19
Visual Outcomes in Presumed Congenital Foveal Toxoplasmosis. 61
32035830 2020
20
Use of a new composite index to demonstrate improved stereoacuity after training on stimuli with dichoptically asymmetric contrast. 61
31735256 2020
21
Comment on the article: multifocal electroretinography in amblyopia. 61
32232567 2020
22
Comparison of Pre-Treatment vs. Post-Treatment Retinal Vessel Density in Children with Amblyopia. 61
32412887 2020
23
Baseline and Clinical Factors Associated with Response to Amblyopia Treatment in a Randomized Clinical Trial. 61
32413002 2020
24
Efficacy of interventions for amblyopia: a systematic review and network meta-analysis. 61
32450849 2020
25
Implied Motion From Form Shows Motion Aids the Perception of Global Form in Amblyopia. 61
32460320 2020
26
Vision training with VEP biofeedback in amblyopia after the critical period. 61
32468275 2020
27
Improved adherence and treatment outcomes with an engaging, personalized digital therapeutic in amblyopia. 61
32433490 2020
28
Reply to the letter to the editor: Multifocal electroretinography in amblyopia. 61
32222829 2020
29
Activation of somatostatin interneurons by nicotinic modulator Lypd6 enhances plasticity and functional recovery in the adult mouse visual cortex. 61
32467358 2020
30
Prevalence, causes and risk factors of reduced VA and persistent reduced VA among preschool children in Eastern China. 61
32462748 2020
31
Deep Learning-Based Prediction of Refractive Error Using Photorefraction Images Captured by a Smartphone: Model Development and Validation Study. 61
32369035 2020
32
Intraocular Pressure Reduction After Real-world Cataract Surgery. 61
32366779 2020
33
Visual Acuity and Foveal Structure in Eyes with Fragmented Foveal Avascular Zones. 61
31956075 2020
34
Clinical spectrum and treatment outcomes of patients with nanophthalmos. 61
32461562 2020
35
Effect of Stimulus Orientation on Visual Function in Children with Refractive Amblyopia. 61
32392311 2020
36
Treatment of Congenital Ptosis in Infants With Associated Amblyopia Using a Frontalis Muscle Flap Eyelid Reanimation Technique. 61
32467524 2020
37
Practice Patterns in the Surgical Management of Pediatric Traumatic Cataracts. 61
32453853 2020
38
Ocular Findings in Pontine Tegmental Cap Dysplasia. 61
32398424 2020
39
Saccadic reaction time and ocular findings in phenylketonuria. 61
32450880 2020
40
Risk factors for spontaneous consecutive exotropia in children with refractive and nonrefractive accommodative esotropia. 61
32108919 2020
41
Evaluation of the Spot Vision Screener in comparison with the orthoptic examination in visual screening in 3-5 year-old schoolchildren. 61
32143821 2020
42
Evaluation of the Spot Vision Screener in School-Aged Children. 61
32453847 2020
43
Detection of Amblyogenic Refractive Error Using the Spot Vision Screener in Children. 61
32413003 2020
44
Short-term Perceptual Learning Game Does Not Improve Patching-Resistant Amblyopia in Older Children. 61
32453851 2020
45
Neuroplasticity in adult human visual cortex. 61
32092315 2020
46
Psychomotor, Psychosocial and Reading Skills in Children with Amblyopia and the Effect of Different Treatments. 61
32281918 2020
47
National and sub national prevalence of Amblyopia and its trends from 1990 to 2018 in Iran. 61
32321688 2020
48
Wiedemann-steiner syndrome with a de novo mutation in KMT2A: A case report. 61
32311999 2020
49
Spectacle correction versus no spectacles for prevention of strabismus in hyperopic children. 61
32240551 2020
50
Influence of prenatal environment and birth parameters on amblyopia, strabismus, and anisometropia. 61
32151573 2020
Sources

Variations for Suppression Amblyopia

About this section
Sources

Expression for Suppression Amblyopia

About this section
Search GEO for disease gene expression data for Suppression Amblyopia.
Sources

Pathways for Suppression Amblyopia

About this section
Sources

GO Terms for Suppression Amblyopia

About this section

Biological processes related to Suppression Amblyopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to glucocorticoid GO:0051384 9.16 HSD11B2 HNMT
2 negative regulation of signaling receptor activity GO:2000272 8.96 MTRNR2L5 MTRNR2L4
3 negative regulation of execution phase of apoptosis GO:1900118 8.62 MTRNR2L5 MTRNR2L4

Molecular functions related to Suppression Amblyopia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor antagonist activity GO:0048019 8.96 MTRNR2L5 MTRNR2L4
2 cell-cell adhesion mediator activity GO:0098632 8.62 SIRPA MYPN
Sources

Sources for Suppression Amblyopia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....